SNORD45B: A Potential Drug Target and Biomarker (G26804)

Target Name: SNORD45B

NCBI ID: G26804

SNORD45B

Other Name(s): RNU45B | U45b | small nucleolar RNA, C/D box 45B | Small nucleolar RNA, C/D box 45B

SNORD45B: A Potential Drug Target and Biomarker

SNORD45B, short for short-chain neurotrophic factor receptor subfamily 45 member B, is a protein that is expressed in various tissues of the brain, including neurons, astrocytes, and pericytes. It is a member of the neurotrophic factor receptor subfamily 45, which is a family of transmembrane proteins that play a crucial role in the development and maintenance of neural function.

SNORD45B is a 21-kDa protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain of SNORD45B consists of a N-terminal region that contains a putative N-methyl-D-aspartate (NMDA) receptor antagonist domain. The transmembrane domain of SNORD45B contains a protein-coding region and a putative intracellular domain that is involved in the formation of SNORD45B-containing tightly packed tightly packed nerve cells.

Function

SNORD45B is involved in various physiological processes in the brain, including neurotransmitter signaling, synaptic plasticity, and neuroprotection. It is a critical regulator of neuronal excitability and is involved in the modulation of pain, anxiety, and depression.

SNORD45B has been shown to play a role in the regulation of pain. Studies have shown that SNORD45B is involved in the modulation of pain perception and that its expression is decreased in individuals with pain-related disorders. Additionally, SNORD45B has been shown to play a role in the regulation of anxiety and depression.

Drug Target

SNORD45B is a potential drug target because of its involvement in various physiological processes that are associated with the development of disease. Its involvement in pain, anxiety, and depression makes it an attractive target for small molecule inhibitors.

One of the potential drug targets for SNORD45B is the inhibition of NMDA receptors, which are involved in pain modulation. NMDA receptors are known for their role in the regulation of pain and have been shown to play a role in the development of pain-related disorders . By inhibiting NMDA receptors, SNORD45B may be able to reduce pain perception and alleviate symptoms of pain-related disorders.

Another potential drug target for SNORD45B is the modulation of synaptic plasticity. SNORD45B has been shown to play a role in the regulation of synaptic plasticity, which is the ability of the nervous system to change and adapt in response to experience. By modulating synaptic plasticity, SNORD45B may be able to contribute to the development of neurodegenerative diseases.

Biomarker

SNORD45B may also be used as a biomarker for various diseases, including pain-related disorders, anxiety, and depression. The expression of SNORD45B is often reduced in individuals with these disorders, which may indicate that SNORD45B plays a role in the development and progression of these diseases.

In conclusion, SNORD45B is a protein that is involved in various physiological processes in the brain, including neurotransmitter signaling, synaptic plasticity, and neuroprotection. Its expression is often reduced in individuals with pain-related disorders, anxiety, and depression, which makes it an attractive target for small molecule inhibitors. Additionally, SNORD45B has been shown to play a role in the regulation of pain, anxiety, and depression, which makes it a potential drug target. Further research is needed to fully understand the role of SNORD45B in these processes and to develop effective treatments for SNORD45B-related disorders.

Protein Name: Small Nucleolar RNA, C/D Box 45B

The "SNORD45B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD45B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets